Novo Mesto, 22 November (STA) - Pharma company Krka posted a group net profit of EUR 121m for the first nine months of the year, up 10% over the year before, with operating profit likewise rising by a tenth to EUR 164m. Group net sales revenue rose by 5% to EUR 972m, the highest January-September sales ever recorded, the company said on Thursday.
The company generated 93% of revenue on foreign markets. Its biggest sales region is Eastern Europe, which accounted for nearly 30% of total revenue. Sales there rose 6%. In Russia, the biggest single market, sales inched up by 2% to EUR 189m.
In Central Europe (Visegrad and Baltic countries), sales also rose by 6% to hit EUR 240m on the back of buoyant sales in Poland, while in Southeastern Europe they surged by 14% to EUR 132m.
In Western Europe, on the other hand, revenue declined by 3% to EUR 211m.
Prescription drugs accounted for four-fifths of all sales and generated revenue of EUR 804m, an increase of 5% over the year before.
The company has a workforce of 11,226 as of the end of September, an increase of 4% over the end of 2017.